Physician profile

William C Loewen

Family Medicine · Wichita, KS

NPI 1992813091

$1,375.86

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $217.97 2019-2022
Amarin Pharma, INC. $152.90 2019-2022
Janssen Pharmaceuticals, INC $130.10 2019-2021
Abbvie INC. $120.16 2019-2022
Amgen INC. $105.49 2019-2022
Novo Nordisk INC $94.88 2019-2022
Astellas Pharma US INC $77.06 2019-2021
Daiichi Sankyo INC. $65.53 2020-2022
Eisai INC. $63.34 2020-2021
Boehringer Ingelheim Pharmaceuticals, INC. $55.44 2019-2022
Astrazeneca Pharmaceuticals LP $47.20 2020-2022
Bayer Healthcare Pharmaceuticals INC. $42.91 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $32.25 2022
Takeda Pharmaceuticals U.S.A., INC. $24.06 2022
Biohaven Pharmaceutical Holding Company LTD. $24.01 2022
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Pacira Therapeutics, INC. $16.33 2020
Electromed, INC. $15.15 2022
Biohaven Pharmaceuticals, INC. $14.52 2021
Glaxosmithkline, LLC. $13.66 2022
Teva Pharmaceuticals USA, INC. $13.32 2020
Merck Sharp & Dohme LLC $12.57 2019
Genentech USA, INC. $12.55 2019
Lilly USA, LLC $12.40 2019
Novartis Pharmaceuticals Corporation $12.06 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William C Loewen

$1,375.86

in general payments reported 2019-2025

Years
2019-2022
Top company
Pfizer INC.

https://glasscript.com/doctor/1188539/william-c-loewen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.